The president of AICARM, Prof. Franco Cecchi, wrote to AIFA to report the serious discomfort experienced by patients with Hypertrophic Obstructive Cardiomyopathy, treated with Ritmodan Retard 250 mg and Ritmodan 100 mg. The shortage of the drug, initially expected until March 2025, has now been extended until September 2025, making access to the therapy even more difficult.
AIFA has taken charge of the report and responded that it is evaluating mitigation actions, which AICARM hopes will be clear, rapid and effective, to guarantee patients therapeutic continuity and safety.
📌 AICARM will continue to monitor the situation and provide updates to patients.
A fascinating journey into DNA and its implications for inherited heart disease: from molecular structure to genetic testing, from possible outcomes to future prospects, to understand the importance of genetics in understanding and managing cardiomyopathies.
